Cephalon is touting Phase III results of its non-Hodgkin's lymphoma drug Treanda. In the trial, 100 patients who were not responding to Genentech and Biogen Idec's Rituxan were given Treanda. The overall response rate was 75 percent and the median duration of response was 40 weeks (9.2 months). The study met its primary endpoints of overall response rate and median duration of response, while demonstrating a manageable tolerability profile.
"We are encouraged that these results replicate those seen in our Phase 2 study, confirming the substantial efficacy in this difficult to treat population," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "Based on these positive results, we are on track to file a New Drug Application in the fourth quarter for Treanda in patients with indolent NHL who have failed treatment with rituximab." Treanda is also being studied as a treatment for chronic lymphocytic leukemia.
- see this release for more
PLUS: Anthera Pharmaceuticals has reported positive results from a Phase II clinical trial of its first compound, A-002, for the treatment of cardiovascular disease. Release
Cephalon takes heat for off-label narcotic promotion. Report
Cephalon shares tank after Sparlon rejection. Report